Four years ago, a Florida woman sued Merck & Co. and was recently awarded $8 million. Her Fosamax Femur Fracture Lawsuits claim that the osteoporosis drug Fosamax was the cause of her damaged jaw. The trail verdict is representative of a major landmark in litigation that totals about 900 lawsuits with pending cases against Merck. These cases of Fosamax lawsuits were filed by nearly 1,280 patient groups who claim that the medication caused the damage of their jawbone tissue. This latest judgment in favor of the woman patient mentioned above is a very important verdict in Fosamax lawsuits.
A recent study, conducted by the American Bone & Mineral Research, concluded that 94% of patients suffering osteoporosis also suffer a rare femur fracture and was traced back to the use of bisphosponate drugs such as Fosamax. A lot of the cases, as shown by the report, say that many of the fractures occur when patients were simply doing low-impact tasks such as walking down a flight of stairs. These reports on people with complaint about femur fracture, at the same time were also Fosamax users, started to come out as early as 2007. A report published in The Journal of Bone and Joint Surgery appeared in the same year. It featured 13 women with low-trauma leg fractures, 9 of whom were long-term Fosamax users.
In Canada, class action lawsuits against Fosamax manufacturer have already popped up. And recently, the Fosamax lawsuits win against Merck may open more doors for major class action lawsuits in the United States. Mostly, patients filing Fosamax lawsuits are claiming that the drug, a prescription treatment used to treat and prevent osteoporosis by increasing bone density and strength, has turned out to actually deteriorate bones. The condition caused a condition known as osteonecrosis of the jaw (or death of jawbone tissue) and contributes to femur fractures. On its part, the manufacturer denies such claims and says that Fosamax is a reliable and efficient prescription medication.
The U.S. Food and Drug Administration (FDA) contacted, in 2008, Merck & Co. Inc., concerning reports of femur fractures associated with their product, Fosamax. Nonetheless, announcement by the FDA was only made in October 2010 that it would require the makers of bisphosphonates to include the risk of femur fracture to the drug’s labeling and a provision for patients on medication guide concerning its risks.
Usually, Fosamax is prescribed to patients in treating menopausal osteoporosis. Moreover, Fosamax has been the subject of so much investigation as of late and is known to be included in a pharmaceutical category called bisphonates. It means that drugs under this category have been linked to thigh fractures. Worse, the drug has been said to cause other serious side effects.